Hospital
Saint Joseph Health System, INC
Saint Joseph Health System, INC was paid $67.41M by Medicaid between Jan 2018 and Dec 2024, across 358 billing codes. Its largest line is 99284, emergency room visit (serious) — 17% of everything it billed.
33Billing provider infoSAINT JOSEPH HEALTH SYSTEM, INC
LEXINGTON, KY 40509
LEXINGTON, KY 40509
33aNPI1447457775assigned 06/29/2007
33bProvider typeGeneral Acute Care Hospital
28Total paid$67.41M
24GClaims1,142,880
24DCodes billed358
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Kentucky
Rank by total paid#11 of 36
Median peer was paid$36.08M
This provider vs. median1.9×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 194,205 | $10.68M | |
| 2019 | 180,380 | $9.70M | |
| 2020 | 187,009 | $9.78M | |
| 2021 | 180,400 | $11.08M | |
| 2022 | 147,504 | $9.45M | |
| 2023 | 144,235 | $9.24M | |
| 2024incomplete | 109,147 | $7.47M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 17% | 31,362 | 23,838 | $11.35M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 14% | 38,796 | 33,110 | $9.57M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 7.2% | 11,548 | 8,432 | $4.86M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.4% | 6,771 | 5,750 | $3.66M |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 2.8% | 43,101 | 36,149 | $1.87M |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 2.7% | 13,193 | 11,730 | $1.82M |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | 2.4% | 3,500 | 2,936 | $1.62M |
| G0378 | Hospital observation service, per hour | 2.1% | 9,847 | 6,072 | $1.40M |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 1.8% | 16,659 | 5,580 | $1.23M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.5% | 23,955 | 18,129 | $1.04M |
| 70450 | Computed tomography, head or brain; without contrast material | 1.5% | 4,606 | 3,852 | $1.03M |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.4% | 19,492 | 15,337 | $962K |
346 more codes
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 1.4% | 2,901 | $961K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.3% | 2,203 | $864K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.3% | 21,383 | $861K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 1.3% | 22,210 | $859K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 1.2% | 3,639 | $829K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | 1.1% | 6,091 | $761K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.1% | 11,462 | $744K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 1,723 | $658K |
| 58662 | <1% | 630 | $648K | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 11,792 | $622K |
| 80053 | Comprehensive metabolic panel | <1% | 47,522 | $581K |
| 71045 | Radiologic examination, chest; single view | <1% | 12,199 | $573K |
| 76830 | Ultrasound, transvaginal | <1% | 2,379 | $538K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | <1% | 7,780 | $524K |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 1,442 | $497K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 710 | $495K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 1,407 | $493K |
| 59025 | Fetal non-stress test | <1% | 5,457 | $460K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,362 | $453K |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | <1% | 636 | $417K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 13,792 | $415K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 52,233 | $387K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 1,476 | $380K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 14,892 | $355K |
| 36415 | Collection of venous blood by venipuncture | <1% | 70,806 | $345K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 663 | $298K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 2,737 | $276K |
| 72131 | <1% | 782 | $273K | |
| 73630 | <1% | 3,540 | $270K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 4,898 | $243K |
| 58558 | <1% | 201 | $237K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 11,739 | $235K |
| 73130 | <1% | 2,984 | $230K | |
| 93458 | <1% | 367 | $224K | |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 2,739 | $218K |
| 73030 | <1% | 2,594 | $209K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 5,310 | $203K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 722 | $201K |
| 76642 | <1% | 2,502 | $199K | |
| 70551 | Magnetic resonance imaging, brain; without contrast material | <1% | 590 | $193K |
| 73610 | <1% | 2,485 | $190K | |
| 72100 | <1% | 2,061 | $188K | |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 3,921 | $177K |
| 69436 | Tympanostomy (requiring insertion of ventilating tube), general anesthesia | <1% | 361 | $166K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 1,328 | $160K |
| 96376 | <1% | 5,419 | $159K | |
| 96367 | <1% | 4,297 | $158K | |
| 83880 | <1% | 5,389 | $150K | |
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | <1% | 2,274 | $132K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 4,672 | $129K |
| 93971 | <1% | 981 | $126K | |
| 84484 | <1% | 11,320 | $123K | |
| C1776 | Joint device (implantable) | <1% | 134 | $122K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 1,281 | $117K |
| 84703 | <1% | 14,134 | $117K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 375 | $114K |
| 73560 | <1% | 1,474 | $113K | |
| 87507 | <1% | 343 | $112K | |
| 0240U | <1% | 1,742 | $108K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 264 | $107K |
| 95811 | <1% | 143 | $105K | |
| 73110 | <1% | 1,510 | $103K | |
| 93017 | <1% | 337 | $101K | |
| 62323 | <1% | 745 | $98K | |
| 74240 | <1% | 645 | $97K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 5,985 | $91K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 3,030 | $90K |
| 83970 | <1% | 2,579 | $88K | |
| 97162 | <1% | 1,551 | $87K | |
| 47562 | <1% | 46 | $86K | |
| J2704 | Injection, propofol, 10 mg | <1% | 13,154 | $86K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 2,930 | $85K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 2,904 | $84K |
| 74018 | <1% | 1,503 | $83K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 5,364 | $83K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 3,594 | $83K |
| 73562 | <1% | 966 | $83K | |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 1,491 | $81K |
| C1769 | Guide wire | <1% | 1,264 | $78K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 4,505 | $72K |
| 81001 | <1% | 24,818 | $72K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 17,167 | $71K |
| 84702 | <1% | 5,420 | $70K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 7,854 | $70K |
| 83690 | <1% | 11,975 | $68K | |
| 96116 | <1% | 670 | $67K | |
| 97161 | <1% | 1,580 | $64K | |
| 83735 | <1% | 10,814 | $64K | |
| 77065 | Tomosynthesis, mammo | <1% | 1,707 | $60K |
| 64493 | <1% | 494 | $60K | |
| 83605 | <1% | 6,404 | $59K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,845 | $59K |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 5,668 | $57K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 8,422 | $56K |
| 96415 | <1% | 1,087 | $56K | |
| 82728 | <1% | 4,373 | $54K | |
| 87486 | <1% | 1,528 | $54K | |
| 80076 | <1% | 3,731 | $54K | |
| 84145 | <1% | 2,515 | $53K | |
| 96136 | <1% | 810 | $53K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 1,551 | $53K |
| 82947 | <1% | 10,816 | $52K | |
| 72040 | <1% | 671 | $52K | |
| 73564 | <1% | 780 | $50K | |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | <1% | 2,904 | $50K |
| 96137 | <1% | 820 | $49K | |
| 77066 | Tomosynthesis, mammo | <1% | 1,434 | $48K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 171 | $47K |
| 99152 | <1% | 1,355 | $45K | |
| 83921 | <1% | 2,536 | $43K | |
| 87040 | <1% | 3,708 | $41K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 12,914 | $41K |
| Q0163 | Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen | <1% | 1,766 | $40K |
| 85027 | <1% | 6,764 | $39K | |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 410 | $39K |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,348 | $38K |
| 80061 | Lipid panel | <1% | 3,320 | $38K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 13,480 | $38K |
| 95806 | <1% | 195 | $37K | |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 1,407 | $37K |
| 73502 | <1% | 686 | $35K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 82 | $34K |
| 87581 | <1% | 1,522 | $33K | |
| J7050 | Infusion, normal saline solution, 250 cc | <1% | 5,104 | $33K |
| 90715 | <1% | 1,141 | $32K | |
| 82330 | <1% | 2,143 | $32K | |
| 82565 | <1% | 3,557 | $32K | |
| 85610 | <1% | 7,809 | $31K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 1,577 | $31K |
| 71250 | <1% | 172 | $31K | |
| 82747 | <1% | 2,102 | $31K | |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 928 | $30K |
| 88307 | <1% | 223 | $30K | |
| 81025 | <1% | 4,223 | $28K | |
| 73080 | <1% | 372 | $28K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,684 | $28K |
| 84112 | <1% | 394 | $27K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,663 | $27K |
| J0694 | Injection, cefoxitin sodium, 1 gm | <1% | 2,025 | $27K |
| 85730 | <1% | 5,878 | $26K | |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 645 | $26K |
| 64494 | <1% | 102 | $26K | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 3,944 | $26K |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 668 | $26K |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | <1% | 169 | $26K |
| 96132 | <1% | 432 | $25K | |
| 84439 | <1% | 1,834 | $25K | |
| C1725 | Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) | <1% | 934 | $25K |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 148 | $25K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 204 | $24K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 7,153 | $24K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 2,632 | $24K |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 1,018 | $24K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 41 | $23K |
| 83540 | <1% | 4,267 | $23K | |
| 76770 | <1% | 136 | $23K | |
| 85379 | <1% | 2,722 | $22K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 425 | $22K |
| 88304 | <1% | 401 | $22K | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 1,947 | $22K |
| 12001 | <1% | 135 | $22K | |
| J2710 | Injection, neostigmine methylsulfate, up to 0.5 mg | <1% | 3,088 | $21K |
| 42820 | Tonsillectomy and adenoidectomy; younger than age 12 | <1% | 32 | $21K |
| 87081 | <1% | 3,172 | $21K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 10,514 | $21K |
| 94761 | <1% | 279 | $20K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 21,620 | $19K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 4,982 | $19K |
| 81003 | <1% | 8,032 | $19K | |
| 70486 | <1% | 66 | $18K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 321 | $18K |
| 87186 | <1% | 1,929 | $18K | |
| 86140 | <1% | 3,930 | $17K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 2,845 | $17K |
| C1762 | Connective tissue, human (includes fascia lata) | <1% | 16 | $16K |
| 86850 | <1% | 2,254 | $16K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 221 | $15K |
| 36591 | <1% | 597 | $15K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 5,273 | $14K |
| 84520 | <1% | 2,011 | $14K | |
| 76536 | <1% | 108 | $14K | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 1,073 | $13K |
| 84436 | <1% | 2,381 | $13K | |
| 85014 | <1% | 1,234 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 5,881 | $13K |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 88 | $13K |
| J2001 | Injection, lidocaine hcl for intravenous infusion, 10 mg | <1% | 9,913 | $13K |
| 83550 | <1% | 1,624 | $12K | |
| 87077 | <1% | 1,211 | $12K | |
| 10060 | <1% | 88 | $12K | |
| 84132 | <1% | 2,240 | $11K | |
| 87088 | <1% | 1,354 | $11K | |
| 64635 | <1% | 54 | $11K | |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | <1% | 708 | $11K |
| A4213 | Syringe, sterile, 20 cc or greater, each | <1% | 1,298 | $10K |
| 74022 | <1% | 122 | $10K | |
| 82435 | <1% | 1,943 | $10K | |
| 84295 | <1% | 1,944 | $10K | |
| 87070 | <1% | 1,951 | $10K | |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 375 | $10K |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 57 | $10K |
| 82550 | <1% | 1,702 | $10K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 4,951 | $9K |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 5,187 | $9K |
| A9577 | Injection, gadobenate dimeglumine (multihance), per ml | <1% | 148 | $9K |
| 97116 | <1% | 356 | $9K | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 1,994 | $9K |
| 72141 | <1% | 26 | $9K | |
| J1644 | Injection, heparin sodium, per 1000 units | <1% | 2,723 | $9K |
| 86900 | <1% | 3,254 | $9K | |
| 82607 | <1% | 645 | $9K | |
| 80050 | General health panel | <1% | 283 | $9K |
| 86901 | <1% | 3,263 | $8K | |
| 77080 | <1% | 94 | $8K | |
| 77061 | <1% | 357 | $8K | |
| 96417 | <1% | 268 | $8K | |
| 73120 | <1% | 99 | $8K | |
| 83615 | <1% | 1,468 | $7K | |
| 77062 | <1% | 290 | $7K | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,816 | $7K |
| 85049 | <1% | 375 | $7K | |
| 72202 | <1% | 91 | $7K | |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 598 | $7K |
| 64636 | <1% | 61 | $7K | |
| 80320 | <1% | 129 | $7K | |
| 73090 | <1% | 85 | $7K | |
| 85652 | <1% | 2,496 | $7K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 105 | $6K |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 5,973 | $6K |
| 82803 | <1% | 305 | $6K | |
| 64450 | <1% | 122 | $6K | |
| 80047 | <1% | 204 | $6K | |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | <1% | 172 | $6K |
| 72070 | <1% | 87 | $6K | |
| 88312 | <1% | 135 | $5K | |
| 87210 | <1% | 1,249 | $5K | |
| 82784 | <1% | 32 | $5K | |
| 84550 | <1% | 1,278 | $5K | |
| M0245 | Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring | <1% | 22 | $5K |
| J3411 | Injection, thiamine hcl, 100 mg | <1% | 1,019 | $5K |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 28 | $5K |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 206 | $5K |
| J3490 | Unclassified drugs | <1% | 1,007 | $4K |
| 70498 | <1% | 15 | $4K | |
| C9113 | Injection, pantoprazole sodium, per vial | <1% | 916 | $4K |
| 73590 | <1% | 59 | $4K | |
| 72128 | <1% | 15 | $4K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 537 | $4K |
| 87205 | <1% | 949 | $4K | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 369 | $4K |
| 20610 | <1% | 25 | $4K | |
| 96102 | <1% | 43 | $4K | |
| J1815 | Injection, insulin, per 5 units | <1% | 1,051 | $3K |
| 84207 | <1% | 149 | $3K | |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 500 | $3K |
| A9575 | Injection, gadoterate meglumine, 0.1 ml | <1% | 80 | $3K |
| 80074 | <1% | 94 | $3K | |
| 94760 | <1% | 266 | $3K | |
| 87807 | <1% | 236 | $3K | |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 1,795 | $3K |
| J1630 | Injection, haloperidol, up to 5 mg | <1% | 686 | $3K |
| 82948 | <1% | 530 | $3K | |
| 87641 | <1% | 97 | $3K | |
| 82731 | <1% | 45 | $3K | |
| 84425 | <1% | 151 | $3K | |
| 82985 | <1% | 198 | $3K | |
| J1030 | Injection, methylprednisolone acetate, 40 mg | <1% | 261 | $3K |
| 99406 | <1% | 154 | $2K | |
| 99153 | Mod sedat endo service >5yrs | <1% | 120 | $2K |
| 29125 | <1% | 27 | $2K | |
| 82746 | <1% | 201 | $2K | |
| 73522 | <1% | 27 | $2K | |
| 76775 | <1% | 18 | $2K | |
| 76870 | <1% | 13 | $2K | |
| 80179 | <1% | 189 | $2K | |
| J1596 | Injection, glycopyrrolate, 0.1 mg | <1% | 222 | $2K |
| 84100 | <1% | 454 | $2K | |
| 36416 | <1% | 341 | $2K | |
| 82378 | <1% | 114 | $2K | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,440 | $2K |
| 90688 | <1% | 129 | $2K | |
| 94729 | <1% | 36 | $2K | |
| 96368 | <1% | 118 | $2K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 23 | $2K |
| 72110 | <1% | 13 | $2K | |
| 80323 | <1% | 14 | $2K | |
| 76000 | <1% | 30 | $2K | |
| J2272 | Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg | <1% | 643 | $1K |
| Q9968 | Injection, non-radioactive, non-contrast, visualization adjunct (e.g., methylene blue, isosulfan blue), 1 mg | <1% | 15 | $1K |
| J2543 | Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) | <1% | 77 | $1K |
| G0008 | Administration of influenza virus vaccine | <1% | 107 | $1K |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 376 | $1K |
| 71101 | <1% | 33 | $1K | |
| 97035 | <1% | 58 | $1K | |
| 93880 | <1% | 14 | $1K | |
| M0239 | Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring | <1% | 13 | $1K |
| 12011 | <1% | 12 | $1K | |
| 81257 | <1% | 14 | $1K | |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 343 | $1K |
| 82533 | <1% | 50 | $971.69 | |
| J0735 | Injection, clonidine hydrochloride, 1 mg | <1% | 716 | $952.62 |
| 73140 | <1% | 13 | $867.31 | |
| J1650 | Injection, enoxaparin sodium, 10 mg | <1% | 118 | $863.51 |
| J1626 | Injection, granisetron hydrochloride, 100 mcg | <1% | 99 | $857.68 |
| 80143 | <1% | 59 | $814.70 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 133 | $807.10 |
| 73060 | <1% | 12 | $784.97 | |
| 84460 | <1% | 171 | $782.36 | |
| 82150 | <1% | 141 | $778.74 | |
| 84450 | <1% | 168 | $757.64 | |
| 94664 | <1% | 128 | $730.27 | |
| 84134 | <1% | 68 | $670.76 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 603 | $654.39 |
| 94060 | <1% | 17 | $649.65 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | <1% | 61 | $648.47 |
| Q0169 | Promethazine hydrochloride, 12.5 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 396 | $644.29 |
| 90837 | Psychotherapy session, about an hour | <1% | 14 | $601.57 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | <1% | 50 | $507.36 |
| 82140 | <1% | 28 | $443.55 | |
| J1453 | Injection, fosaprepitant, 1 mg | <1% | 18 | $431.38 |
| 96523 | <1% | 38 | $365.79 | |
| 86308 | <1% | 44 | $318.31 | |
| J1720 | Injection, hydrocortisone sodium succinate, up to 100 mg | <1% | 15 | $301.88 |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 13 | $244.40 |
| 81015 | <1% | 496 | $236.14 | |
| J1956 | Injection, levofloxacin, 250 mg | <1% | 31 | $226.72 |
| J2003 | Injection, lidocaine hydrochloride, 1 mg | <1% | 218 | $215.19 |
| 82570 | <1% | 95 | $207.42 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 27 | $197.38 |
| 87075 | <1% | 17 | $171.91 | |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 62 | $148.99 |
| 85018 | <1% | 129 | $131.33 | |
| J0595 | Injection, butorphanol tartrate, 1 mg | <1% | 47 | $130.45 |
| J7510 | Prednisolone oral, per 5 mg | <1% | 97 | $122.86 |
| J3105 | Injection, terbutaline sulfate, up to 1 mg | <1% | 42 | $117.53 |
| 84156 | <1% | 60 | $97.63 | |
| J3360 | Injection, diazepam, up to 5 mg | <1% | 12 | $86.08 |
| J2470 | Injection, pantoprazole sodium, 40 mg | <1% | 14 | $81.27 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 25 | $68.10 |
| 82374 | <1% | 34 | $29.72 | |
| 82962 | <1% | 34 | $26.61 | |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | <1% | 15 | $7.16 |
| J2305 | Injection, nitroglycerin, 5 mg | <1% | 17 | $2.46 |
| Q0239 | Injection, bamlanivimab-xxxx, 700 mg | <1% | 13 | $0.24 |
| Q0244 | Injection, casirivimab and imdevimab, 1200 mg | 0% | 34 | $0.00 |
| A9270 | Non-covered item or service | 0% | 901 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialMCINTOSH, KIMBERLY (BUSINESS OFFICE MANAGER)
Parent organizationSAINT JOSEPH HEALTH SYSTEM, INC
| Provider | Location | Paid |
|---|---|---|
| Saint Joseph Health System, INC | Lexington, KY | $85.54M |
| Saint Joseph Health System INC | Martin, KY | $1.90M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.